These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 21408191)
1. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191 [TBL] [Abstract][Full Text] [Related]
2. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
3. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Koprich JB; Johnston TH; Reyes MG; Sun X; Brotchie JM Mol Neurodegener; 2010 Oct; 5():43. PubMed ID: 21029459 [TBL] [Abstract][Full Text] [Related]
4. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638 [TBL] [Abstract][Full Text] [Related]
5. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298 [TBL] [Abstract][Full Text] [Related]
6. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514 [TBL] [Abstract][Full Text] [Related]
7. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Khodr CE; Becerra A; Han Y; Bohn MC Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035 [TBL] [Abstract][Full Text] [Related]
8. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446 [TBL] [Abstract][Full Text] [Related]
9. Novel AAV-based rat model of forebrain synucleinopathy shows extensive pathologies and progressive loss of cholinergic interneurons. Aldrin-Kirk P; Davidsson M; Holmqvist S; Li JY; Björklund T PLoS One; 2014; 9(7):e100869. PubMed ID: 24999658 [TBL] [Abstract][Full Text] [Related]
10. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model. Musacchio T; Rebenstorff M; Fluri F; Brotchie JM; Volkmann J; Koprich JB; Ip CW Ann Neurol; 2017 Jun; 81(6):825-836. PubMed ID: 28470693 [TBL] [Abstract][Full Text] [Related]
11. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression. Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255 [TBL] [Abstract][Full Text] [Related]
12. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. Koprich JB; Johnston TH; Reyes G; Omana V; Brotchie JM PLoS One; 2016; 11(11):e0167235. PubMed ID: 27902767 [TBL] [Abstract][Full Text] [Related]
14. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease. Faustini G; Longhena F; Varanita T; Bubacco L; Pizzi M; Missale C; Benfenati F; Björklund A; Spano P; Bellucci A Acta Neuropathol; 2018 Oct; 136(4):621-639. PubMed ID: 30046897 [TBL] [Abstract][Full Text] [Related]
15. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Maingay M; Romero-Ramos M; Carta M; Kirik D Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952 [TBL] [Abstract][Full Text] [Related]
16. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237 [TBL] [Abstract][Full Text] [Related]
17. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208 [TBL] [Abstract][Full Text] [Related]
18. Ciita Regulates Local and Systemic Immune Responses in a Combined rAAV-α-synuclein and Preformed Fibril-Induced Rat Model for Parkinson's Disease. Fredlund F; Jimenez-Ferrer I; Grabert K; Belfiori LF; Luk K; Swanberg M J Parkinsons Dis; 2024; 14(4):693-711. PubMed ID: 38728204 [TBL] [Abstract][Full Text] [Related]
19. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse. Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655 [TBL] [Abstract][Full Text] [Related]
20. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]